...e path that allows users to take full advantage of...ine two units offers fully programmable paired pul...The ability to change pulse intervals and to contr...00 allows for sub- and supra-threshold conditionin...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
Medicine Products:(Date:5/15/2008)...irstCall/ -- Genesis,Pharmaceuticals Enterprises, ..."Company"), a U.S. pharmaceutical company with its...China, today announced its financial results,for t...rd quarter of its,fiscal year ended June 30, 2008.....S. Securities Exchange Commission that is availab...
(Date:5/15/2008)...irstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasdaq:...joined the company as Vice President, Quality. He ...execution of quality program,strategies for Alexza...ical,product candidates. Mr. Parra was most recent..., Inc. in Palo Alto, California, where he was empl...
(Date:5/15/2008)...nsive Healthcare Plans, Long Term Care Will C...KLAND, Wash., May 15 /PRNewswire-USNewswire/ -- Wi... "Probably," says Cameron Truesdell,CEO of one of...rance,agencies, LTC Financial Partners LLC. Will t...Cain,s -- cover all healthcare needs? "Absolutely,...
(Date:5/15/2008)...-- Congresswoman Lois Capps,(D-CA) and the staff o...d a,briefing for key staff members of the House, o...s., WHEN: Monday, May 19th at 2 PM, WHERE: Ray...cussants includes Mary Hesdorffer, a nurse practit... Applied Research Foundation, who,specializes in a...
Breaking Medicine News(10 mins):Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2... that, diseases are a result of paucity of mineral... of minerals is to maintain the alkaline body pH//...be slightly alkaline and within the range of 7.1 a...utral, while a reading below 7 is acidic. If the p...
...has found that the risk of getting the heart disea...rweight//. Giovanni de Simone and other research...d 4,549 people in American-Indian (native American...Oklahoma, and North and South Dakota, reported sci...
...udy says, drug use, a main factor in two-third (ab...e’ drugs were given to nearly 5 percent of victims...sic sciences at the University of Illinois at Chic... take it as unknowingly, or voluntarily (impairing...
...can now perform gene mapping, ten times faster tha...of linked computers// and unwind the mysteries ass... study, conducted by researchers from Technion-Isr...ublished in the American Journal of Human Genetics...
Other Medicine News:Health News:Sleeping Computers Yield Clues About Genetic Disorders 2(Date:5/15/2008)...nd, May 15 /- Patients with breast or... cancers, can expect,further treatment advances wi...tuzumab) following new data that is being presente...y (ASCO) annual meeting in Chicago at,the end of M...meeting which,is the premier event for cancer ther...
(Date:5/15/2008)...ented at ASCO Showed Acceptable Tolerability Profi...4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /PRNew...nt eribulin mesylate (E7389) demonstrated activity...locally advanced or metastatic,breast cancer, acco...al,trial. The study also suggests that eribulin me...
(Date:5/15/2008)...tions demonstrated in Blacks, Hispanics/Latinos, P...ividuals, PARSIPPANY, N.J., May 15 /...presented at the American Society of,Hypertension,...8) in New,Orleans demonstrated that the powerful c...n medoxomil) safely and effectively helped,patient...
(Date:5/15/2008)...erland, May 15 /- Ergonex Pharma toda...dministration (FDA) has,granted orphan drug design...arterial hypertension (PAH). Terguride is currentl...ial in Europe., "The FDA,s grant of orphan drug d...engthens our development program by offering regul...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Virtual Reality Therapy May Help PTSD Patients 18642 1Virtual Reality Therapy May Help PTSD Patients 18642 2Virtual Reality Therapy May Help PTSD Patients 18642 3Immune system pathway identified to fight allergens asthma 18641 1Immune system pathway identified to fight allergens asthma 18641 2Boston Medical Center Boston University School of Medicine researcher receives award 18638 1Boston Medical Center Boston University School of Medicine researcher receives award 18638 2Boston Medical Center Boston University School of Medicine researcher receives award 18638 3Nitrates in vegetables protect against gastric ulcers 3214 1Nitrates in vegetables protect against gastric ulcers 3214 2Nitrates in vegetables protect against gastric ulcers 3214 3Nitrates in vegetables protect against gastric ulcers 3214 4Nitrates in vegetables protect against gastric ulcers 3214 5...LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abrax...global biopharmaceutical,company, discussed result...nce for chemotherapy induced angiogenesis and,rati...r Injectable,Suspension (paclitaxel protein-bound ...d)) with VEGF inhibitor drugs like,bevacizumab (Av...
...LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abrax...global biopharmaceutical,company, announced result...ole of SPARC (secreted protein acidic and rich in,...rticle,albumin-bound (nab(TM)) tumor-targeting tec...r Research (AACR) Annual Meeting held,April 14-18,...
Other Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5